Eos Advisory
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
TaiSan raises £4.7m in funding led by Eos Advisory and Mercia Ventures for solid-state sodium-ion batteries
TaiSan develops solid-state sodium-ion batteries that are lighter and more compact than existing sodium-ion and lithium-ion alternatives. Its technology is designed for applications such as electric bikes, scooters, vehicles and power tools, offering longer service life and greater safety than conventional flammable liquid electrolytes.
Scarlet Therapeutics raises a £3.2m seed round led by Eos Advisory to advance red blood cell treatments for diseases
Scarlet Therapeutics develops engineered red blood cells designed to treat metabolic diseases and address shortages in rare blood supplies. Scarlet Therapeutics uses synthetic biology and proprietary cell line technology to create lab-grown red blood cells that can be manufactured at scale for therapeutic and transfusion use.
EnsiliTech raises £4.5m seed round led by Eos Advisory to transform global medicine storage and transport
EnsiliTech develops technology that stabilises vaccines and biologics at high temperatures, removing the need for cold-chain storage and improving global access to medicines.
Laverock Therapeutics raises over £20m in expanded seed round led by Calculus Capital to advance gene control therapies
Laverock Therapeutics is developing programmable gene control technologies that enable advanced therapies to respond dynamically to disease, improving precision, safety and effectiveness in cell-based treatments.
Concinnity Genetics raises £3m seed round led by Eos Advisory to establish RNA-based gene therapy control systems
Concinnity Genetics develops RNA based control systems that allow gene and cell therapies to be adjusted after dosing, improving safety and flexibility in advanced medical treatments.
Naturbeads lands £8m Series A led by EOS to tackle microplastic pollution with sustainable cellulose microspheres
Naturbeads produces biodegradable cellulose microspheres that replace microplastics in everyday products, enabling manufacturers to meet regulatory requirements without compromising performance.
More venture news
- 9 Sept 2026
ViaNautisViaNautis secures investment from SCI Ventures to deliver non-viral genetic medicines to cells at spinal cord injury sites
EquityLife Sciences - 9 Sept 2026
CloudNCCloudNC lands £15m in funding led by Nimble Ventures to reduce bottlenecks in precision machining
EquityIndustrial - 9 Sept 2026
KVectorKVector raises £3.8m in funding from VCs to develop low-power radar antennas
EquityTelecoms
